News & Updates

The phase III TACKLE trial highlights a new player in the COVID-19 treatment field – AZD7442 (tixagevimab/cilgavimab) – which demonstrated favourable efficacy and safety for nonhospitalized individuals with mild to moderate symptoms of the disease.

Treatment with remdesivir is associated with reduced risk of hospitalization and death in non-hospitalized and hospitalized COVID-19 patients, respectively, especially when given early during the disease course, according to studies presented at ECCMID 2022.

In the treatment of patients with filamentous fungal keratitis, natamycin performs better than chlorhexidine, being associated with more favourable outcomes, including visual acuity, and fewer adverse events, as shown in a study.

A short intervention that addresses the nocebo (negative placebo) effect appears to improve tolerance of tricyclic antidepressants (TCAs), which are commonly used to treat disorders of gut-brain interaction (DGBI), a study has shown.

Primary norfloxacin prophylaxis is both safe and effective in preventing bacterial infections in patients with acute-on-chronic liver failure (ACLF), a study has shown.

Treatment with ravulizumab leads to rapid and sustained reductions in myasthenia gravis (MG) symptoms, according to the CHAMPION study presented at AAN 2022.